Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer

The safety and efficacy of the additional use of the novel agent pasireotide with the standard regimen of docetaxel and prednisone was explored in patients with metastatic prostate cancer. The results showed tolerability and preliminary efficacy. The combination is worthy of future investigation in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Genitourin Cancer
Main Authors: Thakur, Manish K., Heilbrun, Lance, Dobson, Kimberlee, Boerner, Julie, Stark, Karri, Li, Jing, Smith, Daryn, Heath, Elisabeth, Fontana, Joseph, Vaishampayan, Ulka
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136146/
https://ncbi.nlm.nih.gov/pubmed/29534939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.01.019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados